enVVeno Medical (NVNO) Expected to Post Quarterly Earnings on Thursday

enVVeno Medical (NASDAQ:NVNO) is projected to release its results before the market opens on Thursday, July 30th. Analysts expect enVVeno Medical to post earnings of ($4.69) per share and revenue of $1.00 million for the quarter.

enVVeno Medical (NASDAQ:NVNO) last released its earnings results on Thursday, May 7th. The company reported ($5.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.40) by $2.51. On average, analysts expect enVVeno Medical to post $-16 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

enVVeno Medical Trading Up 5.8%

Shares of NVNO stock opened at $10.73 on Thursday. The stock has a 50 day simple moving average of $10.69 and a 200-day simple moving average of $10.87. The company has a market cap of $7.19 million, a price-to-earnings ratio of -0.42 and a beta of 1.09. enVVeno Medical has a 12-month low of $8.67 and a 12-month high of $184.45.

Wall Street Analysts Forecast Growth

NVNO has been the topic of a number of recent analyst reports. Zacks Research raised enVVeno Medical to a “hold” rating in a report on Tuesday, July 7th. LADENBURG THALM/SH SH raised enVVeno Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 6th. Finally, Weiss Ratings lowered shares of enVVeno Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, enVVeno Medical currently has an average rating of “Hold”.

Institutional Trading of enVVeno Medical

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in enVVeno Medical in the 2nd quarter valued at about $51,000. Creative Planning acquired a new stake in shares of enVVeno Medical during the 2nd quarter worth about $54,000. Geode Capital Management LLC grew its holdings in shares of enVVeno Medical by 1.1% during the second quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock worth $796,000 after buying an additional 2,211 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in shares of enVVeno Medical during the second quarter worth about $5,127,000. Institutional investors and hedge funds own 34.71% of the company’s stock.

enVVeno Medical Company Profile

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.